Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME (BRUNELLO)

9. november 2026 oppdatert av: EyeBiotech Ltd.

En randomisert, dobbeltmasket, multisenter, 3-arm pivotal fase 2/3-studie for å evaluere effektiviteten og sikkerheten til Intravitreal EYE103 sammenlignet med Intravitreal Ranibizumab (0,5 mg) hos deltakere med diabetisk makulaødem

EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig (EYE103) in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME)

In the first year, all 3 treatment groups will be treated every 4 weeks with either remigromig or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm.

Approximately 960 participants will be entered in the study.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME)

Approximately 960 participants will be entered in the study. Participants will be randomized 1:1:1 to receive low dose remigromig, high dose remigromig, or 0.5 mg ranibizumab, administered via intravitreal injection. In the first year, all 3 treatment groups will be treated every 4 weeks with either remigromig or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval (PTI) algorithm. Throughout the 2-year study, subjects will be evaluated every 4 weeks, including measurement of Early Treatment of Diabetic Retinopathy Study (ETDRS) Best-Corrected Visual Acuity (BCVA), examination by slit-lamp biomicroscopy, fundoscopy, and spectral domain optical coherence tomography (SD-OCT). Among other parameters, SD-OCT will be used to measure central subfield thickness (CST) in microns.

Studietype

Intervensjonell

Registrering (Faktiske)

984

Fase

  • Fase 2
  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • CABA, Argentina, 1023
        • Buenos Aires, Argentina
      • Córdoba, Argentina, X5000AAJ
        • Ciudad de Cordoba, Argentina
    • Buenos Aires
      • CABA, Buenos Aires, Argentina, 1015
        • Buenos Aires, Argentina
      • CABA, Buenos Aires, Argentina, 1120
        • Buenos Aires, Argentina
      • CABA, Buenos Aires, Argentina, C1033AAW
        • Buenos Aires, Argentina
      • Caba, Buenos Aires, Argentina, C1116ABA
        • Caba, Buenos Aires, Argentina
    • Córdoba Province
      • Córdoba, Córdoba Province, Argentina, 5000
        • Cordoba, Argentina
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentina, S2000DSK
        • Santa Fe, Argentina
    • Sante Fe
      • Rosario, Sante Fe, Argentina, 2000
        • Santa Fe, Argentina
      • Albury, Australia, 2640
        • Albury, Australia
      • Parramatta, Australia, 2150
        • Parramatta, Australia
      • Sydney, Australia, 2000
        • Sydney, Australia
    • New South Wales
      • Sydney, New South Wales, Australia, 2000
        • Sydney Retina Clinic
      • Sydney, New South Wales, Australia, 2135
        • Sydney, Australia
      • Medellín, Colombia, 50016
        • Medellin, Colombia
    • Antioquia
      • Medellín, Antioquia, Colombia, 50021
        • Medellin, Colombia
    • Atlántico
      • Barranquilla, Atlántico, Colombia, 80002
        • Barranquilla, Colombia
    • Columbia
      • Bogotá, Columbia, Colombia, 110231
        • Bogota, Columbia
    • Valle del Cauca Department
      • Cali, Valle del Cauca Department, Colombia, 760042
        • Cali, Colombia
    • Arizona
      • Scottsdale, Arizona, Forente stater, 85255
        • Scottsdale
    • Arkansas
      • Fayetteville, Arkansas, Forente stater, 72703
        • Fayetteville, Arkansas
      • Springdale, Arkansas, Forente stater, 72764
        • Springdale, Arkansas
    • California
      • Bakersfield, California, Forente stater, 93309
        • Bakersfield, CA
      • Glendale, California, Forente stater, 91204
        • Glendale, CA
      • Modesto, California, Forente stater, 95356
        • Modesto, CA
      • Mountain View, California, Forente stater, 94040
        • Mountain View, CA
      • Redlands, California, Forente stater, 92374
        • Redlands, CA
      • Sacramento, California, Forente stater, 95825
        • Sacramento, CA
      • Sacramento, California, Forente stater, 95841
        • Sacramento, CA
      • Santa Ana, California, Forente stater, 92705
        • Santa Ana
    • Colorado
      • Colorado Springs, Colorado, Forente stater, 80909
        • Colorado Springs, CO
      • Denver, Colorado, Forente stater, 80210
        • Denver, Colorado
    • Connecticut
      • Danbury, Connecticut, Forente stater, 06810
        • Danbury, CT
      • Manchester, Connecticut, Forente stater, 06042
        • Manchester, CT
      • Waterford, Connecticut, Forente stater, 06385
        • Waterford,CT
    • Florida
      • Deerfield Beach, Florida, Forente stater, 33064
        • Deerfield Beach, FL
      • Fort Lauderdale, Florida, Forente stater, 33308
        • Fort Lauderdale, FL
      • Fort Myers, Florida, Forente stater, 33912
        • Fort Myers,FL
      • Gainesville, Florida, Forente stater, 32607
        • Gainesville, FL
      • Orlando, Florida, Forente stater, 32806
        • Orlando, Florida
      • Plantation, Florida, Forente stater, 33324
        • Plantation, FL
      • Sarasota, Florida, Forente stater, 34232
        • Sarasota, FL
      • St. Petersburg, Florida, Forente stater, 33711
        • Saint Petersburg, FL
      • Tallahassee, Florida, Forente stater, 32308
        • Tallahassee, FL
      • Tampa, Florida, Forente stater, 33609-4614
        • Tampa, FL
      • Tampa, Florida, Forente stater, 33617
        • Tampa, FL
      • Winter Haven, Florida, Forente stater, 33880
        • Winter Haven, FL
    • Illinois
      • Lemont, Illinois, Forente stater, 60439
        • Lemont, IL
      • Springfield, Illinois, Forente stater, 62702
        • Springfield, Illinois
    • Iowa
      • West Des Moines, Iowa, Forente stater, 50266
        • West Des Moines, IA
    • Kansas
      • Lenexa, Kansas, Forente stater, 66215
        • Lenexa, Kansas
      • Wichita, Kansas, Forente stater, 67214
        • Wichita, Kansas
    • Maine
      • Portland, Maine, Forente stater, 04101
        • Portland, Maine
    • Maryland
      • Hagerstown, Maryland, Forente stater, 21740
        • Hagerstown, MD
    • Massachusetts
      • Springfield, Massachusetts, Forente stater, 01107
        • Springfield,MA
    • Michigan
      • Grand Rapids, Michigan, Forente stater, 49546
        • Grand Rapids, Michigan
    • Minnesota
      • Minneapolis, Minnesota, Forente stater, 55435
        • Minneapolis, MN
    • Mississippi
      • Madison, Mississippi, Forente stater, 39110
        • Madison, MS
    • New Jersey
      • Bloomfield, New Jersey, Forente stater, 07003
        • Bloomfield, NJ
      • Cherry Hill, New Jersey, Forente stater, 08034
        • Cherry Hill, NJ
    • New York
      • Liverpool, New York, Forente stater, 13088
        • Liverpool, NY
      • Oceanside, New York, Forente stater, 11572
        • Oceanside, NY
      • Rochester, New York, Forente stater, 14620
        • Rochester, NY
    • North Carolina
      • Asheville, North Carolina, Forente stater, 28803
        • Asheville, NC
      • Hickory, North Carolina, Forente stater, 28602
        • Hickory, NC
      • Wake Forest, North Carolina, Forente stater, 27587
        • Wake Forest, MC
      • Winston-Salem, North Carolina, Forente stater, 27103
        • Winston Salem, NC
    • Ohio
      • Cleveland, Ohio, Forente stater, 44122
        • Cleveland, Ohio
      • Cleveland, Ohio, Forente stater, 44130
        • Cleveland, OH
      • Youngstown, Ohio, Forente stater, 44505
        • Youngstown, Ohio
    • Oklahoma
      • Edmond, Oklahoma, Forente stater, 73013
        • Edmond, OK
    • Oregon
      • Portland, Oregon, Forente stater, 97221
        • Portland, OR
      • Springfield, Oregon, Forente stater, 97477
        • Springfield, Oregon
    • Pennsylvania
      • Bethlehem, Pennsylvania, Forente stater, 18017
        • Bethlehem, PA
      • Erie, Pennsylvania, Forente stater, 16507
        • Erie, PA
    • South Carolina
      • Beaufort, South Carolina, Forente stater, 29902
        • Beaufort, SC
      • Florence, South Carolina, Forente stater, 29501
        • Florence, SC
      • Ladson, South Carolina, Forente stater, 29456
        • Ladson, SC
      • West Columbia, South Carolina, Forente stater, 29169
        • West Columbia, SC
    • Tennessee
      • Germantown, Tennessee, Forente stater, 38138
        • Germantown, TN
      • Hixson, Tennessee, Forente stater, 37343
        • Hixson, Tennessee
      • Johnson City, Tennessee, Forente stater, 37604
        • Johnson City, Tennessee
      • Knoxville, Tennessee, Forente stater, 37922
        • Knoxville, TN
      • Nashville, Tennessee, Forente stater, 37203
        • Nashville, TN
    • Texas
      • Abilene, Texas, Forente stater, 79606
        • Abilene, TX
      • Amarillo, Texas, Forente stater, 79109
        • Amarillo, TX
      • Amarillo, Texas, Forente stater, 79106
        • Amarillo, TX
      • Arlington, Texas, Forente stater, 76012
        • Arlington, TX
      • Austin, Texas, Forente stater, 78705
        • Austin, TX
      • Beaumont, Texas, Forente stater, 77707
        • Beaumont, TX
      • Bellaire, Texas, Forente stater, 77401
        • Bellaire, TX
      • Dallas, Texas, Forente stater, 75231
        • Dallas, TX
      • Fort Worth, Texas, Forente stater, 76104
        • Fort Worth, TX
      • Katy, Texas, Forente stater, 77494
        • Katy, TX
      • Plano, Texas, Forente stater, 75075
        • Plano, TX
      • Round Rock, Texas, Forente stater, 78681
        • Round Rock, TX
      • San Antonio, Texas, Forente stater, 78240
        • San Antonio, TX
      • Schertz, Texas, Forente stater, 78154
        • Schertz, Texas
      • The Woodlands, Texas, Forente stater, 77384
        • The Woodlands, TX
      • Willow Park, Texas, Forente stater, 76087
        • Willow Park, TX
    • Utah
      • Salt Lake City, Utah, Forente stater, 84107
        • Salt Lake City, Utah
    • Virginia
      • Lynchburg, Virginia, Forente stater, 24502
        • Lynchburg, VA
      • Richmond, Virginia, Forente stater, 23235
        • Richmond, Virginia
    • Washington
      • Spokane, Washington, Forente stater, 99204
        • Spokane, WA
      • Créteil, Frankrike, 94010
        • Creteil, France
      • Lyon, Frankrike, 69004
        • Lyon, France
      • Marseille, Frankrike, 13008
        • Marseille, France
      • Paris, Frankrike, 75006
        • Paris, France
      • Paris, Frankrike, 75015
        • Paris, France
      • Paris, Frankrike, 75019
        • Paris, France
      • Saint-Cyr-sur-Loire, Frankrike, 37540
        • Saint Cyr sur Loire, France
    • Cedex
      • Dijon, Cedex, Frankrike, 21079
        • Cedex, France
      • Be’er Ya‘aqov, Israel, 70300
        • Beer Yakov, Israel
      • Haifa, Israel, 3436212
        • Haifa, Israel
      • Jerusalem, Israel, 9112001
        • Jerusalem, Israel
      • Petah Tikva, Israel, 49100
        • Petah Tikva, Israel
      • Rehovot, Israel, 76100
        • Rehovot, Israel
      • Tel Aviv, Israel, 6423906
        • Tel Aviv, Israel
      • Bologna, Italia, 40138
        • Bologna, Italy
      • Florence, Italia, 50139
        • Firenze, Italy
      • Milan, Italia, 20122
        • Milano, Italy
      • Milan, Italia, 20132
        • Milano, Italy
      • Milan, Italia, 20157
        • Milano, Italy
      • Roma, Italia, 00168
        • Roma, Italy
      • Rome, Italia, 81.00133
        • Rome, Italy
      • Udine, Italia, 33100
        • Udine, Italy
      • Osijek, Kroatia, 31000
        • Osijek, Croatia
      • Riga, Latvia, LV1002
        • Riga, Latvia
      • Riga, Latvia, LV1006
        • Riga, Latvia
      • Bialystok, Polen, 15-866
        • Bialystok, Poland
      • Bydgoszcz, Polen, 85-309
        • Bydgoszcz, Poland
      • Bydgoszcz, Polen, 85-631
        • Bydgoszcz, Poland
      • Gdansk, Polen, 80-809
        • Gdansk, Poland
      • Katowice, Polen, 40-594
        • Katowice, Poland
      • Krakow, Polen, 31-501
        • Krakow, Poland
      • Olsztyn, Polen, 10-424
        • Olsztyn, Poland
      • Tarnowskie Góry, Polen, 42-600
        • Tarnowskie Gory, Poland
    • Gdansk
      • Gdansk, Gdansk, Polen, 80-809
        • Gdansk, Poland
      • Coimbra, Portugal, 3000-548
        • Coimbra, Portugal
      • Coimbra, Portugal, 3030-163
        • Coimbra, Portugal
      • Porto, Portugal, 4200-319
        • Porto, Portugal
    • PR
      • Arecibo, PR, Puerto Rico, 00612
        • Arecibo, PR
      • Trebišov, Slovakia, 075 01
        • Trebisov, Slovakia
      • Trenčín, Slovakia, 911 01
        • Trencin, Slovakia
      • Žilina, Slovakia, 012 07
        • Zilina, Slovakia
      • Barcelona, Spania, 08035
        • Barcelona, Spain
      • Barcelona, Spania, 08021
        • Barcelona, Spain
      • Barcelona, Spania, 08022
        • Barcelona, Spain
      • Barcelona, Spania, 08195
        • Barcelona, Spain
      • Santiago de Compostela, Spania, 15706
        • Santiago de Compostela, Spain
      • Seville, Spania, 41009
        • Sevilla, Spain
      • Zaragoza, Spania, 50009
        • Zaragoza, Spain
    • Valencia
      • Burjassot, Valencia, Spania, 46100
        • Valencia, Spain
      • Bradford, Storbritannia, BD9 6RJ
        • Bradford, United Kingdom
      • Bristol, Storbritannia, BS1 2LX
        • Bristol, UK
      • Liverpool, Storbritannia, L7 8YA
        • Liverpool, United Kingdom
      • Sunderland, Storbritannia, SR2 9HP
        • Sunderland, United Kingdom
      • Wolverhampton, Storbritannia, WV10 0QP
        • Wolverhamptom, United Kingdom
    • Middlesex
      • London, Middlesex, Storbritannia, NW10 7NS
        • London, UK
    • UnitedKingdom
      • York, UnitedKingdom, Storbritannia, YO10 4DZ
        • York, United Kingdom
      • Mladá Boleslav, Tsjekkia, 293 01
        • Mlada Boleslav, Czechia
      • Náchod, Tsjekkia, 547 01
        • Nachod, Czechia
      • Prague, Tsjekkia, 1150/50
        • Prague, Czechia
      • Prague, Tsjekkia
        • Prague, Czechia
    • Turkey
      • Ankara, Turkey, Tyrkia (Türkiye), 06230
        • Ankara, Turkey
      • Ankara, Turkey, Tyrkia (Türkiye), 06490
        • Ankara, Turkey
      • Balçova, Turkey, Tyrkia (Türkiye), 35330
        • Balcova, Turkey
      • Frankfurt, Tyskland, 60590
        • Frankfurt, Germany
      • Hanover, Tyskland, 30625
        • Hanover, Germany
      • München, Tyskland, 80336
        • Munchen, Germany
      • Münster, Tyskland, 48145
        • Munster, Germany
      • Budapest, Ungarn, H-1062
        • Budapest, Hungary
      • Budapest, Ungarn, H-1085
        • Budapest, Hungary
      • Budapest, Ungarn, H-1106
        • Budapest, Hungary
      • Budapest, Ungarn, H-1133
        • Budapest, Hungry
      • Debrecen, Ungarn, H-4032
        • Debrecen, Hungary
      • Pécs, Ungarn, H-7621
        • Pecs, Hungary
      • Szeged, Ungarn, H-6720
        • Szeged, Hungary
      • Zalaegerszeg, Ungarn, 8900
        • Zalaegerszeg, Hungary
      • Graz, Østerrike, 8036
        • Graz, Austria
      • Innsbruck, Østerrike, 6020
        • Innsbruck, Austria
      • Vienna, Østerrike, 1090
        • Vienna, Austria
      • Vienna, Østerrike, 1140
        • Vienna, Austria

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity
  • Be male or female ≥18 years of age.
  • Have type 1 or type 2 diabetes mellitus and a hemoglobin A1c (HbA1c) of ≤12%.
  • Have a decrease in vision in the study eye determined by the investigator to be primarily the result of diabetic macular edema (DME).

Exclusion Criteria:

  • Be pregnant or breastfeeding

  • History of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of Screening

  • Have any treatment for complications of cataract surgery with steroids or yttrium aluminum garnet (YAG) laser capsulotomy within 90 days of Screening

  • Are currently using drugs with known retinal toxicity (e.g., Hydroxychloroquine, pentosan polysulfate sodium, and amiodarone)

  • If treatment-experienced for DME have a history of any of the following treatments within the noted time windows:

    • Have had prior treatment in the study eye with 8 mg aflibercept (EYLEA HD) or faricimab (VABYSMO) within 120 days prior to the Screening visit in the study eye
    • Have had an IVT with other anti-VEGF treatments (ranibizumab, bevacizumab, aflibercept [2 mg], brolucizumab, pegaptanib sodium) in the study eye within 90 days of the Screening visit

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Remigromig Low Dose Treatment Arm

Remigromig Low Dose Treatment Arm

Remigromig is a humanized antibody formulated for intravitreal administration

Andre navn:
  • Gjenopprett
  • EYE103
Eksperimentell: Remigromig High Dose Treatment Arm

Remigromig High Dose Treatment Arm

Remigromig is a humanized antibody formulated for intravitreal administration

Andre navn:
  • Gjenopprett
  • EYE103
Aktiv komparator: Ranibizumab Treatment Arm

Ranibizumab Treatment Arm

Ranibizumab is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with diabetic macular edema

Andre navn:
  • Lucentis

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from baseline in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart
Tidsramme: Baseline and Week 52

The change from baseline in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart will be presented.

Baseline and Week 52

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from Baseline in Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) at Week 52
Tidsramme: Baseline and Week 52

The change from baseline in Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) at Week 52 will be presented.

Baseline and Week 52
Superiority Hypothesis: Change from Baseline in ETDRS BCVA at Week 52
Tidsramme: Baseline and Week 52

The Superiority Hypothesis: change from baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS) Best-Corrected Visual Acuity (BCVA) at Week 52 will be presented.

Baseline and Week 52
Time to Absence of Diabetic Macular Edema (DME)
Tidsramme: Up to approximately Week 104

The time to absence of Diabetic Macular Edema (DME) defined as Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) of <300 μm will be presented.

Up to approximately Week 104
Time to Gaining ≥15 ETDRS letters
Tidsramme: Up to approximately Week 52

The time to gaining ≥15 letters on the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart will be presented.

Up to approximately Week 52
Proportion of Participants with Resolution of Macular Leakage on FA at Week 24
Tidsramme: Up to approximately Week 24

The proportion of participants with resolution of macular leakage on fluorescein angiography (FA), defined as 0 to 1 mm^2, at Week 24 will be presented.

Up to approximately Week 24
Proportion of Participants Without Intraretinal and Subretinal Fluid at the Foveal Center on OCT at Week 52
Tidsramme: Up to approximately Week 52

The proportion of participants without intraretinal and subretinal fluid at the foveal center on Optical Coherence Tomography (OCT) at Week 52 will be presented.

Up to approximately Week 52
Change from Baseline in Focal Area Zone (FAZ) area on fluorescein angiography (FA) at Week 52
Tidsramme: Baseline and Week 52

The change from baseline in Focal Area Zone (FAZ) area on fluorescein angiography (FA) at Week 52 will be presented.

Baseline and Week 52
Proportion of Participants Achieving 20/40 or Better BCVA at Week 52
Tidsramme: Up to approximately Week 52

The proportion of participants who achieve 20/40 or better Best-Corrected Visual Acuity (BCVA) at Week 52 will be presented.

Up to approximately Week 52
Number of Participants Who Experience an Ocular and/or Systemic Adverse Event (AE)
Tidsramme: Up to approximately 104 Weeks

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an ocular and/or systemic AE will be reported.

Up to approximately 104 Weeks
Number of Participants Who Experience an Ocular and/or Systemic Serious Adverse Event (SAE)
Tidsramme: Up to approximately 104 Weeks

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an ocular and/or systemic serious adverse event (SAE) will be reported.

Up to approximately 104 Weeks
Number of Participants Who Discontinue Study Treatment Due to an AE
Tidsramme: Up to approximately 104 Weeks

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.

Up to approximately 104 Weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: Charles Miller, MD PhD, EyeBiotech Ltd.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

7. august 2024

Primær fullføring (Faktiske)

14. juli 2026

Studiet fullført (Antatt)

14. august 2027

Datoer for studieregistrering

Først innsendt

20. august 2024

Først innsendt som oppfylte QC-kriteriene

22. august 2024

Først lagt ut (Faktiske)

26. august 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • EYE-RES-102
  • MK-3000-001 (Annen identifikator: MSD)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .